SCHEMBL22089284

SCHEMBL22089284

C[C@]12CCC3c4ccc(Cl)cc4CCC3C1[C@H](CCC(=O)O)CC2=O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ STS P08842 3/20 0.59
▸ HSD17B1 P14061 4/20 0.47
▸ LMNA P02545 3/20 0.47
▸ MAPT P10636 3/20 0.47
▸ ESR1 P03372 3/20 0.47
▸ HIF1A Q16665 2/20 0.47
▸ ESR2 Q92731 2/20 0.47
▸ CYP3A4 P08684 2/20 0.47
▸ AKR1B10 O60218 1/20 0.47
▸ SHBG P04278 1/20 0.47
▸ CYP1A2 P05177 1/20 0.47
▸ PGR P06401 1/20 0.47
▸ SERPINA6 P08185 1/20 0.47
▸ AR P10275 1/20 0.47
▸ CYP19A1 P11511 1/20 0.47
▸ AKR1B1 P15121 1/20 0.47
▸ NFKB1 P19838 1/20 0.47
▸ SLC6A4 P31645 1/20 0.47
▸ OPRM1 P35372 1/20 0.47
▸ SNCA P37840 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22088749 1.00 STS (0.59) STSHSD17B1LMNAMAPTESR1
SCHEMBL22524224 0.94 STS (0.53) STSHSD17B1LMNAMAPTESR1
SCHEMBL4893106 0.92 STS (0.69) STSHSD17B1LMNAMAPTESR1
SCHEMBL4893115 0.92 STS (0.69) STSHSD17B1LMNAMAPTESR1
SCHEMBL22088747 0.90 STS (0.48) STSHSD17B1LMNAMAPTESR1
SCHEMBL22088746 0.90 STS (0.48) STSHSD17B1LMNAMAPTESR1
SCHEMBL22089279 0.90 STS (0.48) STSHSD17B1LMNAMAPTESR1
SCHEMBL22236698 0.90 STS (0.48) STSHSD17B1LMNAMAPTESR1
SCHEMBL22088759 0.89 STS (0.58) STSHSD17B1LMNAMAPTESR1
SCHEMBL22089407 0.89 STS (0.58) STSHSD17B1LMNAMAPTESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3634975-B1 17-OXIMES OF 15.BETA.-[3-PROPANAMIDO]-SUBSTITUTED ESTRA-1,3,5(10)-TRIEN-17-ONES FOR USE IN INHIBITION OF 17.BETA.-HYDROXYSTEROID DEHYDROGENASES ORGANON R&D FINLAND LTD (FI) 2024-02-28 — — EP disclosed
US-20220127303-A1 THERAPEUTICALLY ACTIVE STEROIDAL DERIVATIVES FORENDO PHARMA LTD (FI) 2022-04-28 — — US disclosed
US-10717761-B2 Therapeutically active steroidal derivatives FORENDO PHARMA LTD (FI) 2020-07-21 — — US disclosed
WO-2020115371-A1 ESTRA-1,3,5(10)-TRIENE COMPOUNDS CONDENSED IN POSITION 16(17) WITH A PYRAZOLE RING AS INHIBITORS OF 17-HSD1 FORENDO PHARMA LTD (FI) 2020-06-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220127303-A1 THERAPEUTICALLY ACTIVE STEROIDAL DERIVATIVES HSD17B11, NR5A1, CYP17A1 STS 39/4885HSD17B1 4/4885LMNA 2049/4885
US-10717761-B2 Therapeutically active steroidal derivatives HSD17B11, NR5A1, CYP17A1 STS 36/4885HSD17B1 4/4885LMNA 2414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback